(S035) Peripheral and Lymphatic Radiation (RT) Doses With Treatment on RTOG 9413: Immunosuppression or Scattered Doses and Death From Second Cancers? 

Publication
Article
OncologyOncology Vol 28 No 4_Suppl_1
Volume 28
Issue 4_Suppl_1

This study estimates RT doses received by organs of interest during protocol treatment to determine whether the findings might explain these observations.

Josephine Chen, PhD, Alexei Polishchuk, MD, PhD, Bruce A. Faddegon, PhD, Angelica Perez-Andujar, PhD, Mack Roach, MD; University of San Francisco, California

Purpose: Long-term results from Radiation Therapy Oncology Group (RTOG) 9413 show an improvement in biochemical (PSA) failure for patients treated with neoadjuvant androgen suppression (NHT) and whole-pelvis radiotherapy (WPRT) compared with NHT and prostate-only radiation (PORT) but no improvement in survival. There appears to be an increased risk of death from second cancers (SCs), most notably among patients treated with WPRT and adjuvant hormone therapy (AHT), despite the fact that the incidence of SCs is not statistically higher for WPRT. The biologic processes underlying these unexpected results are presently not understood and merit further exploration. This study estimates RT doses received by organs of interest during protocol treatment to determine whether the findings might explain these observations.

Materials and Methods: We generated 6 and 18 MV WPRT (50-Gy pelvic irradiation plus boost) and PORT plans for an adult male phantom in accordance to protocol guidelines, with a total prostate dose of 70 Gy for all four plans. The plans were delivered, photon doses were measured using thermoluminescent dosimeters within the phantom, and Monte Carlo dose calculations were performed. Neutron dose equivalents for 18 MV plans were estimated using literature-reported values. To explore possible RT effects on the immune system, dose-volume histograms for the major lymphatic regions were calculated for WPRT and PORT and compared with an 8-Gy total lymphoid irradiation (TLI) technique, used for immune suppression in patients experiencing heart transplantation rejection.

Results: Ranges of total dose equivalent were estimated for organs associated with death from SCs. Lung and esophageal doses were on the order of 70 mSv for six MV PORT and 70–150 mSv for six MV WPRT. The dose equivalent ranges for 18 MV PORT and WPRT had large contributions from neutrons, and both were on the order of 100–250 mSv. The pancreas dose ranged from 150–250 mSv for PORT and approximately doubled for WPRT. Large ranges were calculated for bladder and rectum, which lay within the treatment field. The colon dose extended to 50 Sv for WPRT but was below 3 Sv for PORT. Approximately one-fourth of the major lymphatics received 8 Gy with WPRT, while one-tenth did so with PORT. The mean lymphatic dose with WPRT was higher than with TLI. 

Conclusion: The estimated scattered doses to organs associated with SC were generally low, and there was large overlap between the dose ranges for WPRT and PORT treatment. This may be reflected in the statistically insignificant difference in SC incidence that was observed. The mean dose to the lymphatics was comparable to mean doses delivered under TLI. This suggests a new hypothesis-that the increased risk of death from SCs may be in part due to pre-existing second cancers that grew more quickly when immune surveillance was compromised. More work in this area is needed.

Proceedings of the 96th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(S002) Outcomes and Prognostic Factors of Stereotactic Body Radiotherapy for Soft Tissue Sarcoma Metastases
(S001) Limb-Sparing Surgery and Intraoperative Radiotherapy in the Treatment of Primary, Nonmetastatic Extremity and Limb-Girdle Soft Tissue Sarcoma
(S003) Disparities in Stage at Diagnosis and Survival in Adult Cancer Patients According to Insurance Status
(S004) Radiation Publications Underrepresented in High-Impact General Medical and Oncology Journals 
(S005) Adjuvant Radiotherapy in Stage II Endometrial Carcinoma: Is Brachytherapy Alone Sufficient for Local Control?
(S006) Extended-Field IMRT With Concomitant Boost for Node-Positive Cervical Cancer: Analysis of Regional Control Rate and Recurrence Pattern
(S007) Stereotactic Radiosurgery to the Brain With Concurrent BRAF Inhibitors for Melanoma Metastases
(S008) Use of Mobile Devices for Creation of Survivorship Care Plans
(S009) Two-Year Outcomes Following Triapine Radiochemotherapy for Cervical Cancer 
(S010) Prospective and Real-Time Data Analysis of Image-Guided Radiotherapy Across a Multinational Pediatrics Consortium: Methodology and Considerations 
(S011) Comparison of Toxicities and Outcomes for Conventional and Hypofractionated Radiation Therapy for Early Glottic Carcinoma
(S013) Adjuvant Radiation Therapy and Temozolomide for Anaplastic Gliomas: The Twelve-Year Washington University Experience
(S014) Gamma Knife Stereotactic Radiosurgery in the Treatment of Brainstem Metastases
(S015) Temporal Lobe Radionecrosis After Skull Base Radiotherapy: Dose-Volume Predictors 
(S012) Prognostic Value of Radiographic Extracapsular Extension in Locally Advanced Non-Oropharyngeal Head and Neck Squamous Cell Cancers
Related Videos
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Adrienne Bruce Shannon, MD, discussed ways to improve treatment and surgical outcomes for patients with dMMR gastroesophageal cancer.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Patient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Treatment options in the refractory setting must improve for patients with resected colorectal cancer peritoneal metastasis, says Muhammad Talha Waheed, MD.
Although immature, overall survival data from the KEYNOTE-868 trial may support the use of pembrolizumab plus chemotherapy in patients with endometrial cancer.
Dostarlimab plus chemotherapy appears to yield favorable overall survival in patients with mismatch repair proficient endometrial cancer.
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Brian Slomovitz, MD, MS, FACOG discusses the use of new antibody drug conjugates for treating patients with various gynecologic cancers.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
Related Content